Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,443
  • Shares Outstanding, K 40,260
  • Annual Sales, $ 102,830 K
  • Annual Income, $ 6,900 K
  • 36-Month Beta 1.32
  • Price/Sales 1.87
  • Price/Cash Flow 18.12
  • Price/Book 2.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.15
  • Number of Estimates 2
  • High Estimate 0.19
  • Low Estimate 0.11
  • Prior Year 0.16
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.63 +3.24%
on 12/14/18
5.40 -11.48%
on 12/03/18
-0.54 (-10.15%)
since 11/16/18
3-Month
4.63 +3.24%
on 12/14/18
6.45 -25.89%
on 09/25/18
-1.12 (-18.98%)
since 09/18/18
52-Week
4.35 +9.89%
on 04/02/18
6.45 -25.89%
on 09/25/18
+0.23 (+5.05%)
since 12/18/17

Most Recent Stories

More News
Kamada (KMDA) Reports Q3 Loss, Misses Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -350.00% and -42.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 4.78 (unch)
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2018,...

KMDA : 4.78 (unch)
Kamada to Present Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference

Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald...

KMDA : 4.78 (unch)
Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

Kamada Ltd. (the "Company") (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the...

KMDA : 4.78 (unch)
Kamada Ltd to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Kamada Ltd (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time.

KMDA : 4.78 (unch)
Kamada Reports Financial Results for First Quarter of 2018

-- U.S. Launch of KEDRAB(R) [Human Rabies Immune Globulin (HRIG)] Represents Significant Company Milestone

KMDA : 4.78 (unch)
Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter ended March 31, 2018, prior to the open of the...

KMDA : 4.78 (unch)
Kedrion Biopharma and Kamada Announce KEDRAB(R) (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Kedrion Biopharma and Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), two leading human-derived protein therapeutics companies, announced today that KEDRAB(R) [Rabies Immune Globulin (Human)]...

KMDA : 4.78 (unch)
Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

Israeli startup Kanabo Research, which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical...

KMDA : 4.78 (unch)
Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Kamada Ltd. (the "Company") (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that the Company recently received feedback from the U.S. Food and Drug Administration...

KMDA : 4.78 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade KMDA with:

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

2nd Resistance Point 4.85
1st Resistance Point 4.82
Last Price 4.78
1st Support Level 4.74
2nd Support Level 4.69

See More

52-Week High 6.45
Fibonacci 61.8% 5.65
Fibonacci 50% 5.40
Fibonacci 38.2% 5.15
Last Price 4.78
52-Week Low 4.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar